Roche has decided to stop developing satralizumab for bone health in Duchenne muscular dystrophy, the company announced.

After following the Olympics, columnist Robin Stemple envisions a future with new treatments and even a cure for FSHD.

Researchers identified a molecular pathway that can limit muscle repair, a finding that may guide future muscular dystrophy treatments.

After years of focusing on her large family, and three sons with Duchenne MD, columnist Betty Vertin is eager to reconnect with friends.